Larimar Therapeutics (LRMR) director buys 5,000 shares in offering

Rhea-AI Filing Summary

Larimar Therapeutics director Frank E. Thomas bought common stock in the company through its underwritten offering. On February 27, 2026, he purchased 5,000 shares of Larimar Therapeutics common stock at $5.00 per share in an open-market style purchase tied to the offering. After this transaction, he directly owned 7,000 shares of common stock.

Insider Trade Summary

Net Buyer: 5,000 shares ($25,000)

Net Buy 1 txn

Insider THOMAS FRANK E

Role Director

Bought 5,000 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$5.00	$25K

Holdings After Transaction: Common Stock — 7,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

THOMAS FRANK E

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PA 19004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		P		5,000(1)	A	$5	7,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026.

	/s/ Jennifer Johansson, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Larimar Therapeutics (LRMR) report for Frank E. Thomas?

Larimar Therapeutics reported that director Frank E. Thomas bought 5,000 shares of common stock. The purchase occurred on February 27, 2026, and was made at $5.00 per share in connection with the company’s underwritten offering that closed on the same date.

How many Larimar Therapeutics (LRMR) shares does Frank E. Thomas own after this Form 4?

After the reported transaction, director Frank E. Thomas directly owns 7,000 shares of Larimar Therapeutics common stock. This reflects the addition of 5,000 shares purchased at $5.00 per share in the underwritten offering that closed on February 27, 2026.

At what price did Frank E. Thomas buy Larimar Therapeutics (LRMR) shares?

Frank E. Thomas bought Larimar Therapeutics common stock at $5.00 per share. The Form 4 states he purchased 5,000 shares at this offering price as part of the company’s underwritten offering, which closed on February 27, 2026.

Was the Larimar Therapeutics (LRMR) insider purchase part of an offering?

Yes. The Form 4 footnote explains that the 5,000 shares of common stock were purchased in Larimar Therapeutics’ underwritten offering at the offering price. The transaction closed on February 27, 2026, aligning the insider’s purchase with the completion of that offering.

Is the Frank E. Thomas Larimar Therapeutics (LRMR) transaction a buy or sell?

The transaction is a buy. The Form 4 lists transaction code “P” and describes it as an open-market purchase, reporting that director Frank E. Thomas acquired 5,000 shares of Larimar Therapeutics common stock at $5.00 per share on February 27, 2026.